
Jeffrey F Peipert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6485029/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effectiveness of Long-Acting Reversible Contraception. New England Journal of Medicine, 2012, 366, 1998-2007.	27.0	932
2	The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. American Journal of Obstetrics and Gynecology, 2010, 203, 115.e1-115.e7.	1.3	503
3	Continuation and Satisfaction of Reversible Contraception. Obstetrics and Gynecology, 2011, 117, 1105-1113.	2.4	448
4	Preventing Unintended Pregnancies by Providing No-Cost Contraception. Obstetrics and Gynecology, 2012, 120, 1291-1297.	2.4	402
5	Prevalence of Bacterial Vaginosis. Obstetrics and Gynecology, 2007, 109, 114-120.	2.4	383
6	Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: Results from the pelvic inflammatory disease evaluation and clinical health (peach) randomized trial. American Journal of Obstetrics and Gynecology, 2002, 186, 929-937.	1.3	372
7	Genital Chlamydial Infections. New England Journal of Medicine, 2003, 349, 2424-2430.	27.0	356
8	Provision of No-Cost, Long-Acting Contraception and Teenage Pregnancy. New England Journal of Medicine, 2014, 371, 1316-1323.	27.0	311
9	Sexually transmitted diseases and infertility. American Journal of Obstetrics and Gynecology, 2017, 216, 1-9.	1.3	282
10	Maternal complications with vaginal birth after cesarean delivery: A multicenter study. American Journal of Obstetrics and Gynecology, 2005, 193, 1656-1662.	1.3	263
11	Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. American Journal of Obstetrics and Gynecology, 2006, 194, 1283-1289.	1.3	249
12	Adnexal Masses in Pregnancy: Surgery Compared With Observation. Obstetrics and Gynecology, 2005, 105, 1098-1103.	2.4	248
13	Age of sexual debut among US adolescents. Contraception, 2009, 80, 158-162.	1.5	239
14	Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception, 2011, 84, 493-498.	1.5	237
15	Maternal Age and Risk of Labor and Delivery Complications. Maternal and Child Health Journal, 2015, 19, 1202-1211.	1.5	196
16	Battering in pregnancy: An assessment of two screening methods. Obstetrics and Gynecology, 1995, 85, 321-325.	2.4	175
17	Obstetric outcomes in women with two prior cesarean deliveries: Is vaginal birth after cesarean delivery a viable option?. American Journal of Obstetrics and Gynecology, 2005, 192, 1223-1228.	1.3	172
18	Twenty-Four–Month Continuation of Reversible Contraception. Obstetrics and Gynecology, 2013, 122, 1083-1091.	2.4	159

#	Article	IF	CITATIONS
19	Contraceptive Failure Rates of Etonogestrel Subdermal Implants in Overweight and Obese Women. Obstetrics and Gynecology, 2012, 120, 21-26.	2.4	155
20	Bacterial vaginosis as a risk factor for upper genital tract infection. American Journal of Obstetrics and Gynecology, 1997, 177, 1184-1187.	1.3	145
21	Efficacy and Safety of Long-Acting Reversible Contraception. Drugs, 2011, 71, 969-980.	10.9	145
22	The effect of birth weight on vaginal birth after cesarean delivery success rates. American Journal of Obstetrics and Gynecology, 2003, 188, 824-830.	1.3	140
23	Continuation of Reversible Contraception in Teenagers and Young Women. Obstetrics and Gynecology, 2012, 120, 1298-1305.	2.4	138
24	Structured contraceptive counseling provided by the Contraceptive CHOICE Project. Contraception, 2013, 88, 243-249.	1.5	132
25	The Contraceptive CHOICE Project Round Up. Clinical Obstetrics and Gynecology, 2014, 57, 635-643.	1.1	129
26	Short Interpregnancy Interval. Obstetrics and Gynecology, 2007, 110, 1075-1082.	2.4	116
27	Trichomoniasis and Other Sexually Transmitted Infections: Results From the 2001–2004 National Health and Nutrition Examination Surveys. Sexually Transmitted Diseases, 2009, 36, 738-744. Screening for bacterial vaginosis in pregnancy21 Reprints are available from the AHRQ Web site at www.ahrq.gov/clinic/uspstfix.htm, through the National Guideline Clearinghouse	1.7	111
28	(www.guideline.gov), or in print through the AHRQ Clearinghouse (1-800-358-9295).221he U.S. Preventive Services Task Force recommendations based on this evidence review can be found in Screening for Bacterial Vaginosis in Pregnancy: Recommendations and Rationale, available elsewhere	3.0	110
29	in this supplement, and from the AHRQ Web site and c. American Journal of Preventive Medicine, 2001, 2 Intrauterine contraception in Saint Louis: a survey of obstetrician and gynecologists' knowledge and attitudes. Contraception, 2010, 81, 112-116.	1.5	108
30	Clinical predictors of endometritis in women with symptoms and signs of pelvic inflammatory disease. American Journal of Obstetrics and Gynecology, 2001, 184, 856-864.	1.3	106
31	Endometritis does not predict reproductive morbidity after pelvic inflammatory disease. American Journal of Obstetrics and Gynecology, 2003, 188, 141-148.	1.3	106
32	Is vaginal birth after cesarean (VBAC) or elective repeat cesarean safer in women with a prior vaginal delivery?. American Journal of Obstetrics and Gynecology, 2006, 195, 1143-1147.	1.3	105
33	Characteristics Associated With Discontinuation of Long-Acting Reversible Contraception Within the First 6 Months of Use. Obstetrics and Gynecology, 2013, 122, 1214-1221.	2.4	103
34	Association of Age and Parity With Intrauterine Device Expulsion. Obstetrics and Gynecology, 2014, 124, 718-726.	2.4	98
35	Violence against Women: Provider Barriers to Intervention in Emergency Departments. Academic Emergency Medicine, 1997, 4, 297-300.	1.8	97
36	Three-year continuation of reversible contraception. American Journal of Obstetrics and Gynecology, 2015, 213, 662.e1-662.e8.	1.3	96

#	Article	IF	CITATIONS
37	Eliminating health disparities in unintended pregnancy with long-acting reversible contraception (LARC). American Journal of Obstetrics and Gynecology, 2016, 214, 681-688.	1.3	96
38	Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception, 2013, 88, 503-508.	1.5	93
39	The role of contraceptive attributes in women's contraceptive decision making. American Journal of Obstetrics and Gynecology, 2015, 213, 46.e1-46.e6.	1.3	92
40	Evaluation of Clinical Methods for Diagnosing Bacterial Vaginosis. Obstetrics and Gynecology, 2005, 105, 551-556.	2.4	91
41	Long-acting reversible contraception inÂadolescents: a systematic review andÂmeta-analysis. American Journal of Obstetrics and Gynecology, 2017, 216, 364.e1-364.e12.	1.3	89
42	Severity of bacterial vaginosis and the risk of sexually transmitted infection. American Journal of Obstetrics and Gynecology, 2011, 205, 113.e1-113.e6.	1.3	83
43	Can uterine rupture in patients attempting vaginal birth after cesarean delivery be predicted?. American Journal of Obstetrics and Gynecology, 2006, 195, 1148-1152.	1.3	82
44	Family Planning as a Cost-Saving Preventive Health Service. New England Journal of Medicine, 2011, 364, e37.	27.0	82
45	Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond FoodÂandÂDrug Administration–approved duration. American Journal of Obstetrics and Gynecology, 2017, 216, 586.e1-586.e6.	1.3	82
46	Human papillomavirus–associated cervical cytologic abnormalities among women with or at risk of infection with human immunodeficiency virus. American Journal of Obstetrics and Gynecology, 2001, 184, 584-590.	1.3	80
47	Electronic Fetal Monitoring as a Public Health Screening Program. Obstetrics and Gynecology, 2010, 116, 1397-1400.	2.4	80
48	Viral Sexually Transmitted Infections and Bacterial Vaginosis: 2001–2004 National Health and Nutrition Examination Survey Data. Sexually Transmitted Diseases, 2008, 35, 791-796.	1.7	78
49	Route of Delivery as a Risk Factor for Emergent Peripartum Hysterectomy. Obstetrics and Gynecology, 2003, 102, 141-145.	2.4	77
50	Pelvic inflammatory disease in adolescents. Current Opinion in Obstetrics and Gynecology, 2006, 18, 503-510.	2.0	77
51	Effectiveness of Treatment Strategies of Some Women With Pelvic Inflammatory Disease. Obstetrics and Gynecology, 2005, 106, 573-580.	2.4	75
52	Use of the Etonogestrel Implant and Levonorgestrel Intrauterine Device Beyond the U.S. Food and Drug Administration–Approved Duration. Obstetrics and Gynecology, 2015, 125, 599-604.	2.4	72
53	Long-Acting Reversible Contraception. New England Journal of Medicine, 2017, 376, 461-468.	27.0	69
54	Bacterial Vaginosis, Race, and Sexually Transmitted Infections: Does Race Modify the Association?. Sexually Transmitted Diseases, 2008, 35, 363-367.	1.7	66

#	Article	IF	CITATIONS
55	Laboratory evaluation of acute upper genital tract infection. Obstetrics and Gynecology, 1996, 87, 730-736.	2.4	64
56	Predicting Failure of a Vaginal Birth Attempt After Cesarean Delivery. Obstetrics and Gynecology, 2007, 109, 800-805.	2.4	63
57	Risk of Bacterial Vaginosis in Users of the Intrauterine Device. Sexually Transmitted Diseases, 2012, 39, 217-222.	1.7	63
58	Hydrolysis of Secreted Sialoglycoprotein Immunoglobulin A (IgA) in ex Vivo and Biochemical Models of Bacterial Vaginosis. Journal of Biological Chemistry, 2012, 287, 2079-2089.	3.4	62
59	Condom Use and the Risk of Recurrent Pelvic Inflammatory Disease, Chronic Pelvic Pain, or Infertility Following an Episode of Pelvic Inflammatory Disease. American Journal of Public Health, 2004, 94, 1327-1329.	2.7	60
60	Contraceptive Failures in Overweight and Obese Combined Hormonal Contraceptive Users. Obstetrics and Gynecology, 2013, 121, 585-592.	2.4	58
61	Oral contraception and the recognition of endometritis. American Journal of Obstetrics and Gynecology, 1997, 176, 580-585.	1.3	57
62	The Influence of Stress on the Menstrual Cycle among Newly Incarcerated Women. Women's Health Issues, 2007, 17, 202-209.	2.0	57
63	Endovaginal sonography for the diagnosis of upper genital tract infection. Obstetrics and Gynecology, 1997, 90, 54-57.	2.4	55
64	Women's Knowledge About Intrauterine Contraception. Obstetrics and Gynecology, 2011, 117, 48-54.	2.4	55
65	Young Age, Nulliparity, and Continuation of Long-Acting Reversible Contraceptive Methods. Obstetrics and Gynecology, 2015, 126, 823-829.	2.4	55
66	Associations between the vaginal microbiome and Candida colonization in women of reproductive age. American Journal of Obstetrics and Gynecology, 2020, 222, 471.e1-471.e9.	1.3	52
67	Epidemiologic Issues of Sexually Transmitted Diseases in Sexual Assault Victims. Obstetrical and Gynecological Survey, 2000, 55, 51.	0.4	52
68	A Randomized Trial of Azithromycin Versus Amoxicillin for the Treatment of Chlamydia trachomatis in pregnancy. Infectious Diseases in Obstetrics and Gynecology, 2001, 9, 197-202.	1.5	50
69	Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study. American Journal of Obstetrics and Gynecology, 2001, 185, 121-127.	1.3	50
70	Association between obesity and bacterial vaginosis as assessed by Nugent score. American Journal of Obstetrics and Gynecology, 2019, 220, 476.e1-476.e11.	1.3	50
71	Sexual Desire and Hormonal Contraception. Obstetrics and Gynecology, 2016, 127, 563-572.	2.4	48
72	Safety and Efficacy of Vaginal Birth After Cesarean Attempts at or Beyond 40 Weeks of Gestation. Obstetrics and Gynecology, 2005, 106, 700-706.	2.4	47

#	Article	IF	CITATIONS
73	Long-acting reversible contraception for adolescents. Current Opinion in Obstetrics and Gynecology, 2012, 24, 293-298.	2.0	46
74	Adolescent Experiences With Intrauterine Devices: A Qualitative Study. Journal of Adolescent Health, 2015, 57, 381-386.	2.5	46
75	Vaginal birth after caesarean delivery: does maternal age affect safety and success?. Paediatric and Perinatal Epidemiology, 2007, 21, 114-120.	1.7	45
76	Comparison of contraceptive method chosen by women with and without a recent history of induced abortion. Contraception, 2011, 84, 571-577.	1.5	45
77	Socioeconomic Status As a Risk Factor for Unintended Pregnancy in the Contraceptive CHOICE Project. Obstetrics and Gynecology, 2017, 130, 609-615.	2.4	45
78	Oligohydramnios. Obstetrical and Gynecological Survey, 1991, 46, 325-339.	0.4	44
79	Risk Factors for Febrile Morbidity After Hysterectomy. Obstetrics and Gynecology, 2004, 103, 86-91.	2.4	44
80	Correlates of Dual-Method Contraceptive Use: An Analysis of the National Survey of Family Growth (2006–2008). Infectious Diseases in Obstetrics and Gynecology, 2012, 2012, 1-6.	1.5	44
81	Interest in and experience with IUD self-removal. Contraception, 2014, 90, 54-59.	1.5	44
82	Relationship between nugent score and vaginal epithelial exfoliation. PLoS ONE, 2017, 12, e0177797.	2.5	42
83	Home Screening Compared With Clinic-Based Screening for Sexually Transmitted Infections. Obstetrics and Gynecology, 2010, 115, 745-752.	2.4	39
84	Type of contraception method used at last intercourse and associations with health risk behaviors among US adolescents. Contraception, 2010, 82, 549-555.	1.5	38
85	Trends in Contraceptive Use Among Women With Human Immunodeficiency Virus. Obstetrics and Gynecology, 2012, 120, 783-790.	2.4	38
86	Efficacy of Clindamycin Vaginal Ovule (3-Day Treatment) vs. Clindamycin Vaginal Cream (7-Day) Tj ETQq0 0 0 rg	BT /Qverlo 1.5	ck 10 Tf 50 2
87	Home versus clinic-based specimen collection for <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> . Expert Review of Anti-Infective Therapy, 2011, 9, 183-194.	4.4	37
88	Association of Lower Genital Tract Inflammation With Objective Evidence of Endometritis. Infectious Diseases in Obstetrics and Gynecology, 2000, 8, 83-87.	1.5	36
89	Positive Testing for <i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i> and the Risk of Pelvic Inflammatory Disease in IUD Users. Journal of Women's Health, 2015, 24, 354-359.	3.3	34
90	Continuation of the Etonogestrel Implant in Women Undergoing Immediate Postabortion Placement. Obstetrics and Gynecology, 2012, 120, 1053-1059.	2.4	34

#	Article	IF	CITATIONS
91	Perceived racial, socioeconomic and gender discrimination and its impact on contraceptive choice. Contraception, 2011, 84, 273-279.	1.5	33
92	Long-term utilization and continuation of intrauterine devices. American Journal of Obstetrics and Gynecology, 2015, 213, 822.e1-822.e6.	1.3	33
93	Design of a stage-matched intervention trial to increase dual method contraceptive use (Project) Tj ETQq1 1	0.784314 rgBT	/Overlock]
94	Reasons for ineffective pre-pregnancy contraception use in patients seeking abortion services. Contraception, 2009, 80, 569-574.	1.5	32
95	A Prevalence Survey of Abuse and Screening for Abuse in Urgent Care Patients. Obstetrics and Gynecology, 1998, 91, 511-514.	2.4	31
96	Surgical Management of Benign Adnexal Masses in the Pediatric/Adolescent Population: An 11-Year Review. Journal of Pediatric and Adolescent Gynecology, 2017, 30, 123-127.	0.7	31
97	Progesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies. Obstetrics and Gynecology, 2000, 95, 227-231.	2.4	30
98	Unplanned Pregnancy. Obstetrics and Gynecology, 2006, 107, 121-127.	2.4	30
99	Understanding prescription adherence: pharmacy claims data from the Contraceptive CHOICE Project. Contraception, 2011, 83, 340-345.	1.5	30
100	The Effect of Prematurity on Vaginal Birth After Cesarean Delivery: Success and Maternal Morbidity. Obstetrics and Gynecology, 2005, 105, 519-524.	2.4	29
101	Adherence to dual-method contraceptive use. Contraception, 2011, 84, 252-258.	1.5	29
102	Fertility after Intrauterine Device Removal: A Pilot Study. European Journal of Contraception and Reproductive Health Care, 2015, 20, 223-230.	1.5	29
103	Noncandidal vaginitis: a comprehensive approach to diagnosis and management. American Journal of Obstetrics and Gynecology, 2020, 222, 114-122.	1.3	29
104	Methodology and Analytic Techniques Used in Clinical Research. Obstetrics and Gynecology, 2009, 114, 877-884.	2.4	27
105	S-Phase Fraction, p53, and HER-2/neu Status as Predictors of Nodal Metastasis in Early Vulvar Cancer. Gynecologic Oncology, 1997, 67, 200-202.	1.4	26
106	Changes in body composition in women using long-acting reversible contraception. Contraception, 2017, 95, 382-389.	1.5	26
107	Increasing long-acting reversible contraceptives: the Australian Contraceptive ChOice pRoject (ACCORd) cluster randomized trial. American Journal of Obstetrics and Gynecology, 2020, 222, S921.e1-S921.e13.	1.3	26
108	Safety and Success of Vaginal Birth after Cesarean Delivery in Patients with Preeclampsia. American Journal of Perinatology, 2006, 23, 145-152.	1.4	25

#	Article	IF	CITATIONS
109	Risk of unintended pregnancy based on intended compared to actual contraceptive use. American Journal of Obstetrics and Gynecology, 2016, 215, 71.e1-71.e6.	1.3	25
110	Reducing health disparities by removing cost, access, and knowledgeÂbarriers. American Journal of Obstetrics and Gynecology, 2017, 216, 382.e1-382.e5.	1.3	25
111	Observational Studies. Clinical Obstetrics and Gynecology, 1998, 41, 235-244.	1.1	25
112	Combination of bacterial vaginosis and leukorrhea as a predictor of cervical chlamydial or gonococcal infection. Obstetrics and Gynecology, 2002, 99, 603-607.	2.4	24
113	Surgical treatments outcomes project for dysfunctional uterine bleeding (STOP-DUB): design and methods. Contemporary Clinical Trials, 2003, 24, 591-609.	1.9	24
114	Contraceptive choice: how do oral contraceptive users differ from condom users and women who use no contraception?. American Journal of Obstetrics and Gynecology, 2008, 198, e46-e47.	1.3	24
115	Home Compared With Clinic-Based Screening for Sexually Transmitted Infections. Obstetrics and Gynecology, 2010, 116, 1311-1318.	2.4	24
116	Comparison of contraceptive use between the Contraceptive CHOICE Project and state and national data. Contraception, 2011, 83, 479-485.	1.5	24
117	Screening for sexually transmitted infections at home or in the clinic?. Current Opinion in Infectious Diseases, 2011, 24, 78-84.	3.1	24
118	Adult Comorbidity Evaluation 27 score as a predictor ofÂsurvival in endometrial cancer patients. American Journal of Obstetrics and Gynecology, 2016, 215, 766.e1-766.e9.	1.3	23
119	Condom use and incident sexually transmitted infection after initiation of long-acting reversible contraception. American Journal of Obstetrics and Gynecology, 2017, 217, 672.e1-672.e6.	1.3	23
120	Anticipated pain as a predictor of discomfort with intrauterine device placement. American Journal of Obstetrics and Gynecology, 2018, 218, 236.e1-236.e9.	1.3	22
121	Identification and recruitment of low-income pregnant smokers. Addictive Behaviors, 2003, 28, 1497-1505.	3.0	21
122	Women at risk for sexually transmitted diseases: correlates of intercourse without barrier contraception. American Journal of Obstetrics and Gynecology, 2007, 197, 474.e1-474.e8.	1.3	21
123	Baseline Correlates of Inconsistent and Incorrect Condom Use Among Sexually Active Women in the Contraceptive CHOICE Project. Sexually Transmitted Diseases, 2011, 38, 1012-1019.	1.7	21
124	A Randomized Trial of Home Versus Clinic-Based Sexually Transmitted Disease Screening Among Men. Sexually Transmitted Diseases, 2012, 39, 842-847.	1.7	21
125	Barriers and facilitators to implementing a patient-centered model of contraceptive provision in community health centers. Contraception and Reproductive Medicine, 2016, 1, 21.	1.9	21
126	Prognostic value of clinical variables in ovarian cancer. Journal of Clinical Epidemiology, 1997, 50, 501-505.	5.0	20

#	Article	IF	CITATIONS
127	Urinary tract infections in women with or at risk for human immunodeficiency virus infection. American Journal of Obstetrics and Gynecology, 2002, 187, 581-588.	1.3	20
128	Diet-controlled gestational diabetes mellitus does not influence the success rates for vaginal birth after cesarean delivery. American Journal of Obstetrics and Gynecology, 2004, 190, 790-796.	1.3	20
129	Change in Sexual Behavior With Provision of No-Cost Contraception. Obstetrics and Gynecology, 2014, 123, 771-776.	2.4	20
130	Systematic reviews of medical evidence: The use of meta-analysis in obstetrics and gynecology. Obstetrics and Gynecology, 1997, 89, 628-633.	2.4	19
131	Positive cone biopsy specimen margins in women infected with the human immunodeficiency virus. American Journal of Obstetrics and Gynecology, 1999, 181, 1395-1399.	1.3	19
132	Association of baseline bleeding pattern on amenorrhea with levonorgestrel intrauterine system use. Contraception, 2016, 94, 556-560.	1.5	19
133	First Trimester Down Syndrome Screening: Public Health Implications. Seminars in Perinatology, 2005, 29, 267-271.	2.5	18
134	Predicting Placental Abruption and Previa in Women with a Previous Cesarean Delivery. American Journal of Perinatology, 2007, 24, 299-305.	1.4	18
135	Association Between Tampon Use and Choosing the Contraceptive Vaginal Ring. Obstetrics and Gynecology, 2010, 115, 735-739.	2.4	17
136	Performance of a checklist to exclude pregnancy at the time of contraceptive initiation among women with a negative urine pregnancy test. Contraception, 2015, 91, 80-84.	1.5	16
137	Medicaid savings from the Contraceptive CHOICE Project: a cost-savings analysis. American Journal of Obstetrics and Gynecology, 2018, 219, 595.e1-595.e11.	1.3	16
138	Effect of staff training and cost support on provision of long-acting reversible contraception in community health centers. Contraception, 2019, 99, 222-227.	1.5	16
139	Strength of indication for cesarean delivery: Comparison of private physician versus resident service labor management. American Journal of Obstetrics and Gynecology, 1999, 181, 435-439.	1.3	15
140	Immediate Postabortion Intrauterine Device Insertion: Continuation and Satisfaction. Women's Health Issues, 2012, 22, e365-e369.	2.0	15
141	Risk-based screening for Chlamydia trachomatis and Neisseria gonorrhoeae prior to intrauterine device insertion. Contraception, 2015, 92, 313-318.	1.5	15
142	Risk Factors for Bladder Injury in Patients With a Prior Hysterotomy. Obstetrics and Gynecology, 2008, 112, 116-120.	2.4	14
143	Reversible Contraception Update: The Importance of Long-Acting Reversible Contraception. Postgraduate Medicine, 2009, 121, 18-25.	2.0	14
144	Cost-Effectiveness Analysis: An Introductory Guide for Clinicians. Obstetrical and Gynecological Survey, 1999, 54, 663-672.	0.4	14

#	Article	IF	CITATIONS
145	Association of the Timing of Postpartum Intrauterine Device Insertion and Breastfeeding With Risks of Intrauterine Device Expulsion. JAMA Network Open, 2022, 5, e2148474.	5.9	14
146	?. Obstetrics and Gynecology, 1995, 86, 302-305.	2.4	13
147	Research Methodology and Analytic Techniques Used in the Journal Obstetrics & Gynecology. Obstetrics and Gynecology, 2005, 106, 808-812.	2.4	13
148	Injectable contraception: issues and opportunities. Contraception, 2014, 89, 331-334.	1.5	13
149	Pharmacy claims data versus patient self-report to measure contraceptive method continuation. Contraception, 2015, 92, 26-30.	1.5	13
150	Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study. Lancet, The, 2022, 399, 2103-2112.	13.7	13
151	Validity of self-reported history of Chlamydia trachomatisÂinfection. American Journal of Obstetrics and Gynecology, 2017, 216, 393.e1-393.e7.	1.3	12
152	Vulvar Vestibulitis:Is It a Defined and Treatable Entity?. Clinical Obstetrics and Gynecology, 1999, 42, 945.	1.1	12
153	Contraceptive continuation in Hispanic women. American Journal of Obstetrics and Gynecology, 2015, 212, 312.e1-312.e8.	1.3	11
154	Screening and Diagnostic Testing. Clinical Obstetrics and Gynecology, 1998, 41, 267-274.	1.1	11
155	The impact of symptoms and comorbidity on prognosis in stage IB cervical cancer. American Journal of Obstetrics and Gynecology, 1993, 169, 598-604.	1.3	10
156	Diagnostic Evaluation of Pelvic Inflammatory Disease. Infectious Diseases in Obstetrics and Gynecology, 1994, 2, 38-48.	1.5	10
157	Research Design and Methods of Quantitative Synthesis of Medical Evidence. Obstetrics and Gynecology, 1997, 90, 473-478.	2.4	10
158	Factors Associated With Increased Charges for Hysterectomy. Obstetrics and Gynecology, 2006, 107, 1057-1063.	2.4	10
159	Marijuana Use among Young Women in a Primary Care Setting. Journal of General Internal Medicine, 2007, 22, 826-829.	2.6	10
160	The Contraceptive CHOICE Project: Recruiting Women at Highest Risk for Unintended Pregnancy and Sexually Transmitted Infection. Journal of Women's Health, 2010, 19, 2233-2238.	3.3	10
161	Dual method use among long-acting reversible contraceptive users. European Journal of Contraception and Reproductive Health Care, 2018, 23, 97-104.	1.5	10
162	A randomized comparison of propofol and methohexital as general anesthetics for vacuum abortion. Contraception, 2003, 68, 211-217.	1.5	9

#	Article	IF	CITATIONS
163	Sexually Transmitted Infection Prevalence in a Population Seeking No-Cost Contraception. Sexually Transmitted Diseases, 2013, 40, 546-551.	1.7	9
164	Contraception and ectopic pregnancy risk: a prospective observational analysis. American Journal of Obstetrics and Gynecology, 2021, 224, 228-229.	1.3	9
165	Predictors of Male Partner Treatment for Sexually Transmitted Infection. Sexually Transmitted Diseases, 2012, 39, 769-775.	1.7	8
166	From research to practice: dissemination of the Contraceptive CHOICE Project. Translational Behavioral Medicine, 2017, 7, 128-136.	2.4	8
167	Long-acting reversible contraception use among residents in obstetrics/gynecology training programs. Open Access Journal of Contraception, 2017, Volume 8, 1-7.	1.4	8
168	Design of the Association of Uterine Perforation and Expulsion of Intrauterine Device study: a multisite retrospective cohort study. American Journal of Obstetrics and Gynecology, 2021, 224, 599.e1-599.e18.	1.3	8
169	Use of the transtheoretical model for behavioral change in women's health. Women's Health Issues, 1998, 8, 304-309.	2.0	7
170	Comparison of unintended pregnancy at 12 months between two contraceptive care programs; a controlled time-trend design. Contraception, 2019, 100, 196-201.	1.5	7
171	Intrauterine device use, sexually transmitted infections, and fertility: a prospective cohort study. American Journal of Obstetrics and Gynecology, 2021, 225, 157.e1-157.e9.	1.3	7
172	Infection: Screening and Management. Journal of Clinical Outcomes Management, 2014, 21, 30-38.	1.7	7
173	Actinomyces: Normal Flora or Pathogen?. Obstetrics and Gynecology, 2004, 104, 1132-1133.	2.4	6
174	Use of the etonogestrel-releasing contraceptive implant. Expert Review of Obstetrics and Gynecology, 2013, 8, 337-344.	0.4	6
175	Comparison of an additional early visit to routine postpartum care on initiation of long-acting reversible contraception: A randomized trial. Contraception, 2018, 98, 223-227.	1.5	6
176	Association of Obesity With Longer Time to Pregnancy. Obstetrics and Gynecology, 2022, 139, 554-560.	2.4	6
177	The economic value of medical research: is it worth the investment?*1. Obstetrics and Gynecology, 2002, 99, 835-840.	2.4	5
178	A Randomized Trial of Buffered Versus Nonbuffered Lidocaine With Epinephrine for Cervical Loop Excision. Journal of Lower Genital Tract Disease, 2014, 18, 8-12.	1.9	5
179	Differences in Contraceptive Discontinuation Among Black and White Women: Evidence from the Contraceptive CHOICE Project. Journal of Women's Health, 2018, 27, 599-606.	3.3	5
180	Evaluation of a computerized contraceptive decision aid: A randomized controlled trial. Contraception, 2020, 102, 339-345.	1.5	5

#	Article	IF	CITATIONS
181	HPV, cervical neoplasia and smoking: knowledge among colposcopy patients. Journal of reproductive medicine, The, 2004, 49, 965-72.	0.2	5
182	Lippes loop and the first IUDs: lessons from aÂbygone era. American Journal of Obstetrics and Gynecology, 2018, 219, 127-128.	1.3	4
183	Prophylactic antibiotic administration prior to hysterectomy: a quality improvement initiative. Journal of reproductive medicine, The, 2004, 49, 949-54.	0.2	4
184	Association between intrauterine device type and risk of perforation and device expulsion: results from the Association of Perforation and Expulsion of Intrauterine Device study. American Journal of Obstetrics and Gynecology, 2022, 227, 57.e1-57.e13.	1.3	4
185	Developing a Youth Contraception Navigator Program: A Human-Centered Design Approach. Journal of Adolescent Health, 2022, , .	2.5	4
186	Cervical Cancer Screening: Primum Non Nocere. Annals of Internal Medicine, 2012, 156, 896.	3.9	3
187	Plan B, One Step not taken: politics trumps science yet again. Contraception, 2012, 85, 340-341.	1.5	3
188	Effect of baseline menstrual bleeding pattern on copper intrauterine device continuation. American Journal of Obstetrics and Gynecology, 2018, 219, 465.e1-465.e5.	1.3	3
189	Influences on condom use: A secondary analysis of women's perceptions from the Australian Contraceptive ChOice pRoject (ACCORd) trial. Australian Journal of General Practice, 2021, 50, 581-587.	0.8	3
190	Clinical predictors of cervical intraepithelial neoplasia 2 or greater in women with mildly abnormal Pap smears. Journal of reproductive medicine, The, 2002, 47, 891-6.	0.2	3
191	Sexual Behavior and Contraceptive Use at Brown University: 1975-2011. Journal of reproductive medicine, The, 2016, 61, 101-8.	0.2	3
192	College Women and Condom Use, 1975–1995. New England Journal of Medicine, 1996, 335, 211-211.	27.0	2
193	Effectiveness of Treatment Strategies of Some Women With Pelvic Inflammatory Disease. Obstetrical and Gynecological Survey, 2006, 61, 23-25.	0.4	2
194	Preventing Unintended Pregnancies by Providing No-Cost Contraception. Obstetrical and Gynecological Survey, 2013, 68, 289-291.	0.4	2
195	Women's satisfaction with and ongoing use of hormonal longâ€acting methods compared to the oral contraceptive pill: Findings from an Australian general practice cluster randomised trial (ACCORd). Australian and New Zealand Journal of Obstetrics and Gynaecology, 2021, 61, 448-453.	1.0	2
196	Copper intrauterine device and incident sexually transmitted infections. American Journal of Obstetrics and Gynecology, 2021, 225, 579-580.	1.3	2
197	Sustainable and effective methods to increase longâ€acting reversible contraception uptake from the ACCORd general practice trial. Australian and New Zealand Journal of Public Health, 2022, 46, 540-544.	1.8	2
198	Ambulatory Gynecology. JAMA - Journal of the American Medical Association, 2000, 283, 2630.	7.4	1

#	Article	IF	CITATIONS
199	Reply. American Journal of Obstetrics and Gynecology, 2015, 212, 255-256.	1.3	1
200	Management of Benign Adnexal Masses in the Pediatric/Adolescent Population. Journal of Pediatric and Adolescent Gynecology, 2016, 29, 180.	0.7	1
201	Increasing the uptake of long-acting reversible contraception in general practice: the Australian Contraceptive ChOice pRoject (ACCORd) cluster randomised controlled trial longitudinal follow-up protocol. BMJ Open, 2020, 10, e035895.	1.9	1
202	Power and Sample Size. Clinical Obstetrics and Gynecology, 1998, 41, 257-266.	1.1	1
203	Association of Comprehensive Immediate Postpartum Contraception With Infant Outcomes. JAMA Pediatrics, 2022, 176, 233.	6.2	1
204	Comparison of procedure time between manual and electric vacuum aspiration for pregnancy termination between 10-14 weeks: A randomized trial. Contraception, 2022, 113, 108-112.	1.5	1
205	Prevalence of Cervical Intraepithelial Neoplasia Grade 2 or 3 in Patients with Atypical Squamous Cells of Undetermined Significance or Low-Grade Squamous Intraepithelial Lesions. Journal of Lower Genital Tract Disease, 1999, 3, 196-200.	1.9	0
206	Discussion: â€~Acceptability of Emergency Contraception' by Rocca et al. American Journal of Obstetrics and Gynecology, 2007, 196, e35-e39.	1.3	0
207	Who chooses emergency contraception: a study by Rocca et al. American Journal of Obstetrics and Gynecology, 2007, 196, 90-91.	1.3	0
208	Electronic Fetal Monitoring as a Public Health Screening Program: The Arithmetic of Failure. Obstetrics and Gynecology, 2011, 117, 730-731.	2.4	0
209	Contraceptive Failures in Overweight and Obese Combined Hormonal Contraceptive Users. Obstetrical and Gynecological Survey, 2013, 68, 736-737.	0.4	0
210	Continuation of the Etonogestrel Implant in Women Undergoing Immediate Postabortion Placement. Obstetrical and Gynecological Survey, 2013, 68, 210-211.	0.4	0
211	Perceived Weight Gain Among Adolescents Using Contraception. Journal of Pediatric and Adolescent Gynecology, 2015, 28, e70.	0.7	0
212	Is It Time to Abandon the Routine Pelvic Examination in Asymptomatic Nonpregnant Women?. JAMA - Journal of the American Medical Association, 2017, 317, 910.	7.4	0
213	Reply. American Journal of Obstetrics and Gynecology, 2017, 216, 192-193.	1.3	0
214	Contraceptive Preference, Continuation Rates, and Unintended Pregnancies in Patients with Comorbidities: A Prospective Cohort Study. Journal of Women's Health, 2021, 30, 1469-1475.	3.3	0
215	Cost-effectiveness of a complex intervention in general practice to increase uptake of long-acting reversible contraceptives in Australiaâ€. Australian Health Review, 2021, 45, 728-734.	1.1	0

216 Contraception and Sterilization. , 2017, , 447-460.

#	Article	IF	CITATIONS
217	Changes in Insurance Status in CHOICE Project Participants. Journal of reproductive medicine, The, 2016, 61, 63-8.	0.2	Ο
218	Knowledge and intention to use long-acting reversible contraception among university students. Journal of American College Health, 0, , 1-4.	1.5	0